Findings of a phase III clinical trial in patients with relapsed or refractory multiple myeloma reveal that addition of elotuzumab, an immunostimulatory monoclonal antibody, to a treatment regimen of lenalidomide and dexamethasone results in a 30% reduction in the risk of disease progression or death. Few adverse events overall were detected in either treatment group, although 10% of patients in the elotuzumab group experienced grade 3 or 4 adverse events. These findings indicate that elotuzumab can be included in existing treatment regimens, and improves the outcomes of patients with relapsed or refractory multiple myeloma.
References
Lonial, S. et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 10.1056/NEJMoa1505654
Rights and permissions
About this article
Cite this article
Elotuzumab reduces risk of multiple myeloma progression. Nat Rev Clin Oncol 12, 502 (2015). https://doi.org/10.1038/nrclinonc.2015.115
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2015.115